Oral oseltamivir treatment of influenza in children
R J Whitley1, F G Hayden, K S Reisinger
1University of Alabama, Birmingham, USA. rwhitley@peds.uab.edu
Insights
Oseltamivir effectively treats influenza in children, reducing illness duration by 26% and lowering otitis media incidence. This well-tolerated antiviral medication is recommended within 48 hours of symptom onset.
Area of Science:
- Pediatric Infectious Diseases
- Antiviral Therapeutics
- Influenza Management
Background:
- Influenza is a significant respiratory illness in children.
- Oral oseltamivir is an established influenza treatment for adults.
- Pediatric influenza treatment efficacy and safety require specific evaluation.
Purpose of the Study:
- To assess the efficacy and safety of oseltamivir in pediatric influenza patients.
- To determine the tolerability of oseltamivir in children aged 1-12 years.
- To evaluate oseltamivir's impact on illness duration and complications.
Main Methods:
- Randomized, double-blind, placebo-controlled trial.
- Involved children aged 1-12 years with influenza symptoms onset <48 hours.
- Oseltamivir (2 mg/kg/dose) or placebo administered twice daily for 5 days.
Main Results:
- Oseltamivir reduced median illness duration by 36 hours (26%) compared to placebo (P < 0.0001).
- Treatment decreased cough, coryza, fever duration, and otitis media diagnoses by 44%.
- Oseltamivir was well-tolerated, with a 5.8% incidence of emesis; adverse event discontinuation was low.
Conclusions:
- Oral oseltamivir is an effective and well-tolerated treatment for influenza in children.
- Early administration (within 48 hours of onset) is crucial for efficacy.
- Oseltamivir therapy reduces influenza-related complications and antibiotic use in children.
Background:
Oral oseltamivir administration is effective treatment for influenza in adults. This study was conducted to determine the efficacy, safety and tolerability of oseltamivir in children with influenza.
Methods:
In this randomized, double blind, placebo-controlled study, children 1 through 12 years with fever [> or =100 degrees F (> or =38 degrees C)] and a history of cough or coryza <48 h duration received oseltamivir 2 mg/kg/dose or placebo twice daily for 5 days. The primary efficacy endpoint was the time to resolution of illness including mild/absent cough and coryza mild/absent, return to normal activity and euthermia.
Results:
Of 695 enrolled children 452 (65%) had influenza (placebo, n = 235; oseltamivir, n = 217). Among infected children the median duration of illness was reduced by 36 h (26%) in oseltamivir compared with placebo recipients (101 h; 95% confidence interval, 89 to 118 vs. 137 h; 95% confidence interval, 125 to 150; P < 0.0001). Oseltamivir treatment also reduced cough, coryza and duration of fever. New diagnoses of otitis media were reduced by 44% (12% vs. 21%). The incidence of physician-prescribed antibiotics was significantly lower in influenza-infected oseltamivir (68 of 217, 31%) than placebo (97 of 235, 41%; P = 0.03) recipients. Oseltamivir therapy was generally well-tolerated, although associated with an excess frequency of emesis (5.8%). Discontinuation because of adverse events was low in both groups (1.8% with oseltamivir vs. 1.1% with placebo). Oseltamivir treatment did not affect the influenza-specific antibody response.
Conclusions:
Oral oseltamivir administration is an efficacious and well-tolerated therapy for influenza in children when given within 48 h of onset of illness.
Related Concept Videos
01:27Influenza
01:29Respiratory Syncytial Virus Disease
01:25Inhibitors Of Virion Release
01:16Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
01:15Upper Respiratory Drugs: First and Second-Generation Antihistamines
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...